Successful treatment of EGFR-mutated non-small cell lung cancer with reduced-dose gefitinib: A case report

Epidermal growth factor receptor (EGFR) mutation is a favorable prognostic factor of non-small cell lung cancer (NSCLC). In the majority of patients with EGFR mutations, clinical benefits of EGFR-tyrosine kinase inhibitors (TKIs) have been reported. One of the TKIs, gefitinib, appears to be less tox...

全面介紹

Na minha lista:
書目詳細資料
發表在:Exp Ther Med
Main Authors: WATANABE, HIROKO, TAMURA, TOMOHIRO, KAGOHASHI, KATSUNORI, TAKAYASHIKI, NORIO, KURISHIMA, KOICHI, SATOH, HIROAKI, HIZAWA, NOBUYUKI
格式: Artigo
語言:Inglês
出版: D.A. Spandidos 2015
主題:
Articles
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4487036/
https://ncbi.nlm.nih.gov/pubmed/26170967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2015.2499
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍